Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Fiche publication
Date publication
août 2023
Journal
Breast cancer (Tokyo, Japan)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Dr COUDERT Bruno, Pr COUTANT Charles, Dr LADOIRE Sylvain, Dr HENNEQUIN Audrey, Dr MAYEUR Didier
Tous les auteurs :
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S
Lien Pubmed
Résumé
Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis.
Mots clés
Breast cancer, HER2 low, HER2 zero, Neoadjuvant chemotherapy, Pathologic complete response
Référence
Breast Cancer. 2023 08 10;: